Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAZA PET-MRI for Hypoxia Imaging in Pancreatic Cancer
NCT04395469Active, not recruiting
- Sponsor
- University Health Network
- Start
- May 2021
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of Fluoroazomycin arabinoside F-18 in pancreatic adenocarcinoma (PDAC), sponsored by University Health Network. Primary endpoint: Tumor Hypoxia at 2.5 years. Started May 2021; status: active, not recruiting.
02
Drugs
Fluoroazomycin arabinoside F-18
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04395469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04395469.